In two recent phase 3 studies (SINUS-24 and SINUS-52), dupilumab, a human monoclonal antibody that inhibits IL-4 and IL-13 signaling, reduced the nasal polyp size and the severity of the sinonasal symptoms and improved olfactory dysfunction and quality of life in adult patients with severe CRSwNP [162]. The gene discussed is IL13; the disease is chronic rhinosinusitis with nasal polyps.